Oddo BHF - SM Cap Q1 sales previews: slight growth before the trade war with the US

Report

Oddo BHF

Emmanuel Matot ...

Sarra Maatki

S&M Cap Q1 sales previews: slight growth before the trade war with the US

07/04/2025 1 EN

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Emmanuel Matot

Sarra Maatki

Other Reports from Oddo BHF

Martial Descoutures ... (+2)

Martial Descoutures
Oussema Denguir

Cellectis : Cellectis: the reference player in allogeneic CAR-T cells

Cellectis is the French specialist in allogeneic CAR-T cells, now mainly developed in cancer treatment. Its first CAR-T in partnership with Servier and Allogene is currently in the pivot phase in first-line diffuse B-cell lymphoma, while its most advanced own CAR-T candidate is expected to enter into the pivot phase II in H2 this year in acute lymphoblastic leukaemia. Bolstered by a recent deal with AstraZeneca, which acquired a stake in the company (+44%), we are initiating coverage of the stock with an Outperform rating and target price of € 6.5 (+480%).

10h / 9m 10h / 9m 1 EN

Martial Descoutures ... (+2)

Martial Descoutures
Oussema Denguir

Cellectis : Cellectis : l’acteur de référence des CAR-T allogéniques

Cellectis est le spécialiste français des CAR-T allogéniques, développés aujourd’hui essentiellement dans le traitement des cancers. Son premier CAR-T partenarisé à Servier et Allogene est actuellement en phase pivot en 1ere L du lymphome diffus à cellules B alors que son candidat CAR-T propre le plus avancé devrait entrer en phase 2 pivot au S2 de cette année en Leucémie Lymphoïde Aigue. Fort d’un accord récent avec AstraZeneca qui a pris une participation dans la société (44%), nous initions la couverture du titre avec une recommandation à Surperformance et un OC de 6.5 € (+480%).

10h / 21m 10h / 21m 1 FR

Mateo Salcedo

Mateo Salcedo

Prysmian : 2028 roadmap and potential hybrid bond issuance

On March 26, Prysmian held a CMD to update investors less than two years after its last CMD as the company has already surpassed the targets set back then. Looking into the roadmap set for 2028, both the Transmission and the Digital Solutions segments are expected to be the main growth drivers. We believe that the targets set for 2028 are achievable amid good organic growth and continued bolt-on M&A. We expect net leverage to continue to decrease y/y supported by the strong FCF generation and expected limited M&A before 2027 as the company focuses on the recently acquired Encore Wire and Chann...

10h / 21m 10h / 21m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

S&M Cap Q1 sales previews: slight growth before the trade war with the US

Cellectis : Cellectis: the reference player in allogeneic CAR-T cells

Cellectis : Cellectis : l’acteur de référence des CAR-T allogéniques

Prysmian : 2028 roadmap and potential hybrid bond issuance

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe